Monday, May 18, 2020 10:54:48 AM
November, 2005
https://www.businesswire.com/news/home/20051107005498/en/NanoViricides-Reports-Initial-Safety-Results-Anti-Influenza-Bird
Novel Influenza and Bird Flu Therapeutics Moving Rapidly at NanoViricides, Inc. September, 2007
https://www.businesswire.com/news/home/20070904005487/en/Influenza-Bird-Flu-Therapeutics-Moving-Rapidly-NanoViricides
NanoViricides is on Course to Develop Bird Flu, Influenza, and Other Drugs January, 2008.
https://www.businesswire.com/news/home/20080122005644/en/NanoViricides-Develop-Bird-Flu-Influenza-Drugs
NanoViricides, Inc. Release: Anti-Dengue NanoViricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever June, 2010
https://www.biospace.com/article/releases/nanoviricides-inc-release-anti-dengue-nanoviricides-achieve-significant-protection-in-initial-in-vivo-studies-on-dengue-hemorrhagic-fever-/
NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency November, 2013
http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Announces%20that%20DengueCide%E2%84%A2%20Has%20Received%20Orphan%20Drug%20Designation%20From%20the%20European%20Medicines%20Agency%20(EMA).html
NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference June, 2014
https://www.businesswire.com/news/home/20140714005478/en/NanoViricides-President-Dr.-Diwan-Presented-FluCide-Data
NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates September, 2014
http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Reports%20That%20It%20Has%20Designed%20and%20Commenced%20Synthesis%20of%20Novel%20Ebola%20Drug%20Candidates.html
NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model April 2015
https://www.biospace.com/article/releases/nanoviricides-inc-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model-/
NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruse June 2016
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology October, 2017
http://www.nanoviricides.com/press%20releases/2017/NanoViricides%20to%20Present%20Results%20On%20Successful%20Treatment%20Of%20Herpes-Induced%20Acute%20Retinal%20Necrosis%20at%20the%20Annual%20Meeting.html
NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials May, 2018
https://www.biospace.com/article/releases/nanoviricides-provides-update-says-company-is-stable-and-is-moving-steadily-towards-clinical-trials/?s=86
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html
NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials Feb, 2019
https://www.accesswire.com/567044/NanoViricides-Files-Quarterly-Report-for-Period-Ending-September-30-2019--HerpeCide-Drug-Candidate-IND-Enabling-Studies-Update-Progressing-Towards-Clinical-Trials
NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses. May 12, 2020
https://ih.advfn.com/stock-market/AMEX/nanoviricides-NNVC/stock-news/82433957/nanoviricides-develops-highly-effective-broad-spec
Yeeeeeeepppppp... Any time now.....
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM